Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes

Dateline City:
KENILWORTH, N.J.& NEW YORK Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA® (sitagliptin) or MetforminKENILWORTH, N.J.& NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Pfizer Inc. (NYSE:FE), today announced that the U.S.Language:
EnglishContact: Merck Media:Doris Li, [phone]orMerck Investor:Amy Klug, [phone]orKristen Drake, [phone]orPfizer Media:Steve Danehy, [phone]orPfizer Investor:Ryan Crowe, [phone]Ticker Slug:Ticker:MRKExchange:NYSETicker:FEExchange:NYSE
@Merckread more

Source: Merck.com - Research and Development News - March 6, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK #Pfizer $MRK $PFE Januvia MSD NYSE:MRK Source Type: news